Last reviewed · How we verify
FF Inhalation Powder
FF Inhalation Powder is a Inhaled corticosteroid Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.
FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | FF Inhalation Powder |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate is a potent inhaled corticosteroid designed for pulmonary delivery. It binds to glucocorticoid receptors in the airways and lungs, suppressing inflammatory cell recruitment and reducing production of inflammatory mediators, thereby decreasing airway inflammation and improving airflow obstruction in respiratory diseases.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year (PHASE4)
- Functional Respiratory Imaging Study (PHASE3)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF Inhalation Powder CI brief — competitive landscape report
- FF Inhalation Powder updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FF Inhalation Powder
What is FF Inhalation Powder?
How does FF Inhalation Powder work?
What is FF Inhalation Powder used for?
Who makes FF Inhalation Powder?
What drug class is FF Inhalation Powder in?
What development phase is FF Inhalation Powder in?
What are the side effects of FF Inhalation Powder?
What does FF Inhalation Powder target?
Related
- Drug class: All Inhaled corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD)
- Compare: FF Inhalation Powder vs similar drugs
- Pricing: FF Inhalation Powder cost, discount & access